U.S. markets close in 3 hours 32 minutes

  • S&P 500

    4,314.89
    +16.03 (+0.37%)
     

  • Dow 30

    33,939.60
    +62.82 (+0.19%)
     

  • Nasdaq

    13,361.11
    +101.96 (+0.77%)
     

  • Russell 2000

    1,873.11
    +7.41 (+0.40%)
     

  • Crude Oil

    67.53
    -2.64 (-3.76%)
     

  • Gold

    1,968.20
    -9.00 (-0.46%)
     

  • Silver

    24.05
    -0.36 (-1.50%)
     

  • EUR/USD

    1.0748
    -0.0001 (-0.01%)
     

  • 10-Yr Bond

    3.7780
    +0.0330 (+0.88%)
     

  • GBP/USD

    1.2494
    -0.0088 (-0.70%)
     

  • USD/JPY

    139.7040
    +0.3490 (+0.25%)
     

  • Bitcoin USD

    25,860.50
    -8.69 (-0.03%)
     

  • CMC Crypto 200

    566.42
    +0.72 (+0.13%)
     

  • FTSE 100

    7,570.69
    +8.33 (+0.11%)
     

  • Nikkei 225

    32,434.00
    +168.83 (+0.52%)
     

After Delaying Earnings, Catalent Posts Larger-Than-Expected Q3 Loss Due To Production Challenges

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • CTLT

  • Catalent Inc (NYSE: CTLT) announced its Q3 FY23 results after delaying it twice last month.

  • The company reported revenue of $1.04 billion, down 19% as reported, or 17% in constant currency, beating the consensus of $952.66 million.

  • Overall organic net revenue decreased by 19% over the same period.

  • "We continue to make progress in addressing our previously announced operational challenges while also completing our strategic investments in high-demand, high-growth areas and executing a company-wide cost-reduction plan," said Alessandro Maselli, President & CEO.

  • The company reported an adjusted net loss was $(17) million, or $(0.09) per diluted share, compared to a profit of $188 million, or $1.04 per diluted share, a year ago and the consensus loss of $(0.03).

  • In April, Catalent reported productivity challenges and higher-than-expected costs at its drug product and drug substance manufacturing facilities in Bloomington, Indiana, and Brussels, Belgium.

  • Guidance: The company expects FY23 sales of $4.225-$4.325 billion, compared to previous guidance of $4.25-$4.35 billion and the consensus of $4.29 billion.

  • Catalent forecasts adjusted EBITDA of $700 million - $750 million, down from $725 million - $775 million expected earlier, and adjusted net income of $169 million - $210 million versus $187 million - $228 million expected earlier.

  • Price Action: CTLT shares are up 3.07% at $40.01 premarket on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article After Delaying Earnings, Catalent Posts Larger-Than-Expected Q3 Loss Due To Production Challenges originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.